Stanley Erck, Novavax CEO (AP Images)
October 27, 2021 04:46 PM EDTUpdated October 28, 07:39 AM
Coronavirus

No­vavax takes pro­tein-based Covid-19 vac­cine over­seas, ask­ing for an ap­proval in the UK

Paul Schloesser

Associate Editor

Just af­ter an on­slaught of man­u­fac­tur­ing is­sues last week and sub­mit­ting their Covid-19 vac­cine to the WHO for re­view last month, No­vavax is go­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times